What is the share price of Everest Organics Ltd (EVERESTO) today?
The share price of EVERESTO as on 5th December 2025 is ₹437.90. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Everest Organics Ltd (EVERESTO) share?
The past returns of Everest Organics Ltd (EVERESTO) share are- Past 1 week: 0.41%
- Past 1 month: 2.94%
- Past 3 months: 11.04%
- Past 6 months: 4.83%
- Past 1 year: 206.66%
- Past 3 years: 246.81%
- Past 5 years: 61.82%
What are the peers or stocks similar to Everest Organics Ltd (EVERESTO)?
The peers or stocks similar to Everest Organics Ltd (EVERESTO) include:What is the market cap of Everest Organics Ltd (EVERESTO) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Everest Organics Ltd (EVERESTO) is ₹424.50 Cr as of 5th December 2025.What is the 52 week high and low of Everest Organics Ltd (EVERESTO) share?
The 52-week high of Everest Organics Ltd (EVERESTO) is ₹477 and the 52-week low is ₹142.10.What is the PE and PB ratio of Everest Organics Ltd (EVERESTO) stock?
The P/E (price-to-earnings) ratio of Everest Organics Ltd (EVERESTO) is -331.64. The P/B (price-to-book) ratio is 6.07.Which sector does Everest Organics Ltd (EVERESTO) belong to?
Everest Organics Ltd (EVERESTO) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Everest Organics Ltd (EVERESTO) shares?
You can directly buy Everest Organics Ltd (EVERESTO) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Everest Organics Ltd
EVERESTO Share Price
437.904.54% (+19.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
EVERESTO Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
EVERESTO Performance & Key Metrics
EVERESTO Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 64.42 | 6.07 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.87 | 5.82 | 0.59% |
EVERESTO Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
EVERESTO Company Profile
Everest Organics Limited is a pharmaceutical company engaged in the business of bulk drugs, intermediates and active pharmaceutical ingredients (APIs).
SUNPHARMA
PE Ratio
39.63
39.63
1Y Return
0.45%
0.45%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.04
67.04
1Y Return
12.63%
12.63%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.51%
1.51%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.77
18.77
1Y Return
2.85%
2.85%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.21
29.21
1Y Return
1.24%
1.24%
Buy Reco %
72.22
72.22
EVERESTO Forecast
EVERESTO Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
EVERESTO
EVERESTO
Income
Balance Sheet
Cash Flow
Annual Normal View
EVERESTO Income Statement
EVERESTO Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 107.87 | 112.87 | 156.39 | 168.66 | 182.63 | 202.26 | 189.98 | 198.13 | 160.17 | 188.86 | ||||||||||
Raw Materials | 71.32 | 72.98 | 97.00 | 103.52 | 117.13 | 141.72 | 126.31 | 124.64 | 98.53 | 170.78 | ||||||||||
| Power & Fuel Cost | 9.54 | 10.34 | 10.81 | 11.85 | 12.36 | 14.70 | 18.88 | 15.40 | 14.83 | |||||||||||
| Employee Cost | 8.74 | 9.34 | 11.64 | 13.30 | 15.26 | 16.33 | 16.30 | 18.98 | 16.35 | |||||||||||
| Selling & Administrative Expenses | 5.45 | 5.54 | 6.33 | 7.34 | 7.65 | 8.66 | 9.75 | 10.93 | 9.12 | |||||||||||
| Operating & Other expenses | 5.84 | 6.89 | 12.24 | 11.92 | 6.32 | 12.21 | 10.88 | 16.30 | 13.42 | |||||||||||
EBITDA | 6.98 | 7.78 | 18.37 | 20.73 | 23.91 | 8.64 | 7.86 | 11.88 | 7.92 | 18.08 | ||||||||||
| Depreciation/Amortization | 2.45 | 2.68 | 2.84 | 3.21 | 3.37 | 3.80 | 4.47 | 5.80 | 5.96 | 6.07 | ||||||||||
| PBIT | 4.53 | 5.10 | 15.53 | 17.52 | 20.54 | 4.84 | 3.39 | 6.08 | 1.96 | 12.01 | ||||||||||
| Interest & Other Items | 2.76 | 2.74 | 3.21 | 3.43 | 3.26 | 3.10 | 3.31 | 5.47 | 5.19 | 5.09 | ||||||||||
| PBT | 1.77 | 2.36 | 12.32 | 14.09 | 17.28 | 1.74 | 0.08 | 0.61 | -3.23 | 6.92 | ||||||||||
| Taxes & Other Items | 0.43 | 0.65 | 4.82 | 3.20 | 3.56 | 0.60 | 0.28 | 0.47 | -1.95 | 0.33 | ||||||||||
| Net Income | 1.34 | 1.71 | 7.50 | 10.89 | 13.72 | 1.14 | -0.20 | 0.14 | -1.28 | 6.59 | ||||||||||
| EPS | 2.37 | 2.14 | 9.38 | 13.61 | 17.15 | 1.42 | -0.25 | 0.18 | -1.45 | 6.79 | ||||||||||
| DPS | 0.00 | 0.00 | 1.00 | 1.00 | 1.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.11 | 0.07 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EVERESTO Company Updates
EVERESTO Stock Peers
EVERESTO Past Performance & Peer Comparison
EVERESTO Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Everest Organics Ltd | -331.64 | 6.07 | — |
| Sun Pharmaceutical Industries Ltd | 39.63 | 5.98 | 0.89% |
| Torrent Pharmaceuticals Ltd | 67.04 | 16.88 | 0.85% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
EVERESTO Stock Price Comparison
Compare EVERESTO with any stock or ETFCompare EVERESTO with any stock or ETF
EVERESTO
EVERESTO Holdings
EVERESTO Shareholdings
EVERESTO Promoter Holdings Trend
EVERESTO Promoter Holdings Trend
Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 1.45%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
EVERESTO Institutional Holdings Trend
EVERESTO Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
EVERESTO Shareholding Pattern
EVERESTO Shareholding Pattern
EVERESTO Shareholding History
EVERESTO Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing EVERESTO stock
smallcases containing EVERESTO stock
Looks like this stock is not in any smallcase yet.
EVERESTO Events
EVERESTO Events
EVERESTO Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
EVERESTO Dividend Trend
No dividend trend available
EVERESTO Upcoming Dividends
EVERESTO Upcoming Dividends
No upcoming dividends are available
EVERESTO Past Dividends
EVERESTO Past Dividends
Cash Dividend
Ex DateEx DateSep 15, 2022
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 15, 2022
Cash Dividend
Ex DateEx DateSep 8, 2021
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 8, 2021
Cash Dividend
Ex DateEx DateFeb 17, 2021
Interim
Interim | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Feb 17, 2021
Cash Dividend
Ex DateEx DateSep 1, 2020
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 1, 2020
Cash Dividend
Ex DateEx DateSep 3, 2019
Final
Final | Div/Share: ₹1.00
Dividend/Share
₹1.00
Ex DateEx Date
Sep 3, 2019
EVERESTO Stock News & Opinions
EVERESTO Stock News & Opinions
Articles & Videos
Earnings
Everest Organics standalone net profit rises 56.76% in the September 2025 quarter
Net profit of Everest Organics rose 56.76% to Rs 1.16 crore in the quarter ended September 2025 as against Rs 0.74 crore during the previous quarter ended September 2024. Sales rose 15.78% to Rs 51.00 crore in the quarter ended September 2025 as against Rs 44.05 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales51.0044.05 16 OPM %10.087.79 - PBDT4.202.22 89 PBT2.680.75 257 NP1.160.74 57 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Everest Organics schedules board meeting
Everest Organics will hold a meeting of the Board of Directors of the Company on 12 November 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Everest Organics to conduct AGM
Everest Organics announced that the 32th Annual General Meeting(AGM) of the company will be held on 27 September 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Everest Organics reports standalone net profit of Rs 1.41 crore in the June 2025 quarter
Net profit of Everest Organics reported to Rs 1.41 crore in the quarter ended June 2025 as against net loss of Rs 6.09 crore during the previous quarter ended June 2024. Sales rose 65.82% to Rs 53.81 crore in the quarter ended June 2025 as against Rs 32.45 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales53.8132.45 66 OPM %8.27-11.28 - PBDT3.69-4.62 LP PBT2.17-6.09 LP NP1.41-6.09 LP Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Everest Organics to conduct board meeting
Everest Organics will hold a meeting of the Board of Directors of the Company on 5 August 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Everest Organics standalone net profit rises 4750.00% in the March 2025 quarter
Net profit of Everest Organics rose 4750.00% to Rs 2.91 crore in the quarter ended March 2025 as against Rs 0.06 crore during the previous quarter ended March 2024. Sales declined 22.22% to Rs 40.93 crore in the quarter ended March 2025 as against Rs 52.62 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 1.29 crore in the year ended March 2025 as against net profit of Rs 0.14 crore during the previous year ended March 2024. Sales declined 19.14% to Rs 159.48 crore in the year ended March 2025 as against Rs 197.24 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales40.9352.62 -22 159.48197.24 -19 OPM %8.405.61 -4.535.57 - PBDT2.512.01 25 2.726.41 -58 PBT0.950.16 494 -3.240.61 PL NP2.910.06 4750 -1.290.14 PL Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Everest Organics schedules board meeting
Everest Organics will hold a meeting of the Board of Directors of the Company on 27 May 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Spotlight
Everest Organics hits the roof after securing KDMF nod for Rabeprazole Sodium API
The Rabeprazole Sodium API is primarily used to treat conditions related to excessive stomach acid production, including gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome, as it acts as a proton pump inhibitor (PPI) by significantly reducing the amount of acid produced in the stomach, essentially helping to heal ulcers and alleviate symptoms like heartburn and acid reflux. According to the regulatory filing, the company revealed that the approval, granted in February 2025, allows it to export its Rabeprazole Sodium API to the South Korean market. Everest Organics is engaged in the manufacturing of active pharmaceutical ingredients and bulk drugs. The company's standalone net profit surged to Rs 1.14 crore in Q3 FY25 as against Rs 0.02 crore posted in Q3 FY24. However, revenue from operations fell 19.9% YoY to Rs 42.05 crore in the quarter ended 31 December 2024. Powered by Capital Market - Live
9 months agoCapital Market - Live
Earnings
Everest Organics standalone net profit rises 5600.00% in the December 2024 quarter
Net profit of Everest Organics rose 5600.00% to Rs 1.14 crore in the quarter ended December 2024 as against Rs 0.02 crore during the previous quarter ended December 2023. Sales declined 19.92% to Rs 42.05 crore in the quarter ended December 2024 as against Rs 52.51 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales42.0552.51 -20 OPM %9.565.35 - PBDT2.621.49 76 PBT1.150.16 619 NP1.140.02 5600 Powered by Capital Market - Live
9 months agoCapital Market - Live
Corporate
Everest Organics to conduct board meeting
Everest Organics will hold a meeting of the Board of Directors of the Company on 11 February 2025.Powered by Capital Market - Live
10 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -1.03%, vs industry avg of 10.04%
Over the last 5 years, market share decreased from 0.07% to 0.04%